Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery
- 5 August 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 108 (5), 542-547
- https://doi.org/10.1161/01.cir.0000081770.51929.5a
Abstract
Background— Aspirin inhibits platelet activation and reduces atherothrombotic complications in patients at risk of myocardial infarction and stroke. However, a sufficient inhibition of platelet function by aspirin is not always achieved. The causes of this aspirin resistance are unknown. Methods and Results— Patients undergoing coronary artery bypass grafting (CABG) have a high incidence of aspirin resistance. To evaluate functional and biochemical responses to aspirin, platelet-rich plasma was obtained before and at days 1, 5, and 10 after CABG. Thromboxane formation, aggregation, and α-granule secretion were effectively inhibited by 30 or 100 μmol/L aspirin in vitro before CABG, but this inhibition was prevented or attenuated after CABG. Whereas the inhibition of thromboxane formation and aggregation by aspirin in vitro partly recovered at day 10 after CABG, oral aspirin (100 mg/d) remained ineffective. The inducible isoform of cyclooxygenase in platelets, COX-2, has been suggested to confer aspirin resistance. In fact, immunoreactive COX-2 was increased 16-fold in platelets at day 5 after CABG, but the COX-2 selective inhibitor celecoxib did not alter aspirin-resistant thromboxane formation. By contrast, the combined inhibitor of thromboxane synthase and thromboxane receptor antagonist terbogrel equally prevented thromboxane formation of platelets obtained before (control) and after CABG. Conclusions— Platelet aspirin resistance involves an impairment of both in vivo and in vitro inhibition of platelet functions and is probably due to a disturbed inhibition of platelet COX-1 by aspirin.Keywords
This publication has 21 references indexed in Scilit:
- The way I see it: House officers need formal career developmentBMJ, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Towards a definition of aspirin resistance: a typological approachPlatelets, 2002
- Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteersBritish Journal of Clinical Pharmacology, 2001
- Molecular and Transcriptional Regulation of Megakaryocyte DifferentiationThe International Journal of Cell Cloning, 2001
- Coagulation, Fibrinolysis and Platelet P-selectin Expression in Peripheral Vascular DiseaseEuropean Journal of Vascular and Endovascular Surgery, 2001
- Habitual smoking causes an abnormality in platelet thromboxane A 2 metabolism and results in an altered susceptibility to aspirin effectsPlatelets, 2000
- CYCLOOXYGENASES 1 AND 2Annual Review of Pharmacology and Toxicology, 1998
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- Kinetics of Aspirin Absorption Following Oral Administration of Six Aqueous Solutions with Different Buffer CapacitiesJournal of Pharmaceutical Sciences, 1984